Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

708 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Three-month tapering and discontinuation of long- term, low-dose glucocorticoids in senior patients with rheumatoid arthritis is feasible and safe: placebo-controlled double blind tapering after the GLORIA trial.
Almayali AAH, Boers M, Hartman L, Opris D, Bos R, Kok MR, Da Silva JA, Griep E, Klaasen R, Allaart CF, Baudoin P, Raterman HG, Szekanecz Z, Buttgereit F, Masaryk P, Lems W, Smulders Y, Cutolo M, Ter Wee MM. Almayali AAH, et al. Among authors: bos r. Ann Rheum Dis. 2023 Oct;82(10):1307-1314. doi: 10.1136/ard-2023-223977. Epub 2023 Aug 4. Ann Rheum Dis. 2023. PMID: 37541762 Clinical Trial.
Stopping Tumor Necrosis Factor Inhibitor Treatment in Patients With Established Rheumatoid Arthritis in Remission or With Stable Low Disease Activity: A Pragmatic Multicenter, Open-Label Randomized Controlled Trial.
Ghiti Moghadam M, Vonkeman HE, Ten Klooster PM, Tekstra J, van Schaardenburg D, Starmans-Kool M, Brouwer E, Bos R, Lems WF, Colin EM, Allaart CF, Meek IL, Landewé R, Bernelot Moens HJ, van Riel PL, van de Laar MA, Jansen TL; Dutch National POET Collaboration. Ghiti Moghadam M, et al. Among authors: bos r. Arthritis Rheumatol. 2016 Aug;68(8):1810-7. doi: 10.1002/art.39626. Arthritis Rheumatol. 2016. PMID: 26866428 Clinical Trial.
Early rheumatoid arthritis treated with tocilizumab, methotrexate, or their combination (U-Act-Early): a multicentre, randomised, double-blind, double-dummy, strategy trial.
Bijlsma JWJ, Welsing PMJ, Woodworth TG, Middelink LM, Pethö-Schramm A, Bernasconi C, Borm MEA, Wortel CH, Ter Borg EJ, Jahangier ZN, van der Laan WH, Bruyn GAW, Baudoin P, Wijngaarden S, Vos PAJM, Bos R, Starmans MJF, Griep EN, Griep-Wentink JRM, Allaart CF, Heurkens AHM, Teitsma XM, Tekstra J, Marijnissen ACA, Lafeber FPJ, Jacobs JWG. Bijlsma JWJ, et al. Among authors: bos r. Lancet. 2016 Jul 23;388(10042):343-355. doi: 10.1016/S0140-6736(16)30363-4. Epub 2016 Jun 7. Lancet. 2016. PMID: 27287832 Clinical Trial.
Remarkable international variability in reasons for ineligibility and non-participation in the GLORIA trial.
Hartman L, Bos R, Buttgereit F, Güler-Yuksel M, Ionescu R, Kok MR, Lems WF, Micaelo M, Opris-Belinski D, Pusztai A, Santos E, Da Silva J, Szekanecz Z, Zeiner K, Zhang D, Boers M. Hartman L, et al. Among authors: bos r. Scand J Rheumatol. 2019 Jul;48(4):340-341. doi: 10.1080/03009742.2018.1559880. Epub 2019 May 27. Scand J Rheumatol. 2019. PMID: 31132016 No abstract available.
Effectiveness and safety over 3 years after the 2-year U-Act-Early trial of the strategies initiating tocilizumab and/or methotrexate.
Verhoeven MMA, Tekstra J, Welsing PMJ, Pethö-Schramm A, Borm MEA, Bruyn GAW, Bos R, Griep EN, Klaasen R, van Laar JM, Lafeber FPJG, Bijlsma JWJ, de Hair MJH, Jacobs JWG. Verhoeven MMA, et al. Among authors: bos r. Rheumatology (Oxford). 2020 Sep 1;59(9):2325-2333. doi: 10.1093/rheumatology/kez602. Rheumatology (Oxford). 2020. PMID: 31859346 Free PMC article. Clinical Trial.
Medication adherence in older people with rheumatoid arthritis is lower according to electronic monitoring than according to pill count.
Hartman L, Cutolo M, Bos R, Opris-Belinski D, Kok MR, Griep-Wentink HJRM, Klaasen R, Allaart CF, Bruyn GAW, Raterman HG, Voshaar MJH, Gomes N, Pinto RMA, Klausch LT, Lems WF, Boers M. Hartman L, et al. Among authors: bos r. Rheumatology (Oxford). 2021 Nov 3;60(11):5239-5246. doi: 10.1093/rheumatology/keab207. Rheumatology (Oxford). 2021. PMID: 33682887 Free PMC article. Clinical Trial.
Low dose, add-on prednisolone in patients with rheumatoid arthritis aged 65+: the pragmatic randomised, double-blind placebo-controlled GLORIA trial.
Boers M, Hartman L, Opris-Belinski D, Bos R, Kok MR, Da Silva JA, Griep EN, Klaasen R, Allaart CF, Baudoin P, Raterman HG, Szekanecz Z, Buttgereit F, Masaryk P, Klausch LT, Paolino S, Schilder AM, Lems WF, Cutolo M; GLORIA Trial consortium. Boers M, et al. Among authors: bos r. Ann Rheum Dis. 2022 Jul;81(7):925-936. doi: 10.1136/annrheumdis-2021-221957. Epub 2022 May 31. Ann Rheum Dis. 2022. PMID: 35641125 Free PMC article. Clinical Trial.
Cost-effectiveness and cost-utility of add-on, low-dose prednisolone in patients with rheumatoid arthritis aged 65+: The pragmatic, multicenter, placebo-controlled GLORIA trial.
Hartman L, El Alili M, Cutolo M, Opris D, Da Silva J, Szekanecz Z, Buttgereit F, Masaryk P, Bos R, Kok MR, Paolino S, Coupé V, Lems WF, Boers M; GLORIA consortium. Hartman L, et al. Among authors: bos r. Semin Arthritis Rheum. 2022 Dec;57:152109. doi: 10.1016/j.semarthrit.2022.152109. Epub 2022 Oct 21. Semin Arthritis Rheum. 2022. PMID: 36335684 Free article. Clinical Trial.
Changes in body weight and body composition in patients with active rheumatoid arthritis aged 65+ treated with 2-year low-dose add-on prednisolone in the randomised double-blind placebo-controlled GLORIA trial.
Güler-Yüksel M, Kuijper M, Bos R, Molenaar E, Emmering J, Eshuis S, Human A, Reimann F, Boers M, Kok MR. Güler-Yüksel M, et al. Among authors: bos r. RMD Open. 2023 Jun;9(2):e002905. doi: 10.1136/rmdopen-2022-002905. RMD Open. 2023. PMID: 37349120 Free PMC article. Clinical Trial.
708 results